icon bookmark-bicon bookmarkicon cameraicon checkicon chevron downicon chevron lefticon chevron righticon chevron upicon closeicon v-compressicon downloadicon editicon v-expandicon fbicon fileicon filtericon flag ruicon full chevron downicon full chevron lefticon full chevron righticon full chevron upicon gpicon insicon mailicon moveicon-musicicon mutedicon nomutedicon okicon v-pauseicon v-playicon searchicon shareicon sign inicon sign upicon stepbackicon stepforicon swipe downicon tagicon tagsicon tgicon trashicon twicon vkicon yticon wticon fm

Head of Russia's Sovereign Wealth Fund says its Sputnik V Covid-19 vaccine carries fewer risks than rival British formula

Head of Russia's Sovereign Wealth Fund says its Sputnik V Covid-19 vaccine carries fewer risks than rival British formula
The pause in trials of Britain's Oxford/AstraZeneca Covid-19 vaccine after an adverse reaction in a participant shows how risky the technology is, and why the developers of Russia's Sputnik V have chosen another platform.

That's according to Kirill Dmitriev, CEO of the Russian Direct Investment Fund, which is bankrolling the Russian formula's development. He was speaking as it was revealed that the British trials were resumed on Saturday with the approval of national regulators.

AstraZeneca announced the suspension of its phase-three trial on Tuesday, after one of the trial participants suffered a “serious adverse reaction.” 

“We are delighted that AstraZeneca has resumed its trials and continues to move forward,” said Dmitriev. 

At the same time, the suspension of trials clearly showed the fallacy of the approach, when entire countries exclusively rely on novel and untested platforms when choosing a vaccine.

AstraZeneca’s vaccine uses a monkey adenovirus that shares a gene with the Covid-19 coronavirus – a platform that hasn’t been subjected to any long-term studies. Russia’s Sputnik V, in contrast, uses human adenoviruses as a vector – an approach that has been studied extensively for more than half a century.

Also on rt.com Sputnik V questions ANSWERED: Head of team financing world’s first Covid-19 vaccine explains formula to critics

Dmitriev added that the push by Western pharmaceutical companies for indemnity from lawsuits over vaccines illustrates the uncertainty surrounding monkey adenoviruses and mRNA technology – another untested method of vaccine development. AstraZeneca was granted immunity from legal action earlier this summer, while a legal framework to shield pharmaceutical firms already exists in the US.

“Russia will not follow such an approach,” he said, “as it has demonstrated the safety and efficiency of its human adenoviral vector platform, including its Sputnik V vaccine.”

The first batches of Sputnik V have been sent out to all of Russia’s 85 regions, with deliveries expected on Monday. Earlier this month, respected British medical journal The Lancet confirmed that the vaccine was 100 percent effective and caused no serious adverse effects, but stressed the need for further long-term trials, due to the relatively small sample size. 

Also on rt.com Only 42% of Americans would take a Covid-19 vaccine before November, poll reveals, as Trump hints at jab by election day

Russia was criticized in the West for allegedly rushing the development of Sputnik V, and for rolling out the vaccine before concluding a third stage of clinical trials. However, Dmitriev stressed that earlier stages had been just as effective as those conducted by Western pharmaceutical companies, and that the human adenovirus platform has long been regarded as safe.

Sputnik V’s phase-three trials began last month and preliminary results will be published in the coming two months. The Russian shot is the world’s first Covid-19 vaccine to be registered and distributed since the pandemic began. 

Think your friends would be interested? Share this story!

Podcasts